Healthcare Realty Trust enters the week with the most decisive analyst move in months landing on its doorstep — and the stock's response so far has been muted, which makes the setup worth examining carefully.
Raymond James reinstated coverage on June 17 with an Outperform rating and a $24 target, flipping from a prior Underperform stance. That is a full bull-to-bear reversal from a named analyst, and the $24 target sits well above the current price of $20.50. The broader Street has been directionally constructive for weeks. Since early May, Wells Fargo, RBC, UBS, Scotiabank, Citigroup, and Cantor Fitzgerald all raised targets — in every case maintaining existing ratings rather than upgrading. The consensus price target now sits near $20.82, barely above the current price, which tells you most of those firms have already been caught up by the rally. The Raymond James reinstatement is the first action in this cycle that actually implies material upside from here.
Short positioning is modest and not moving aggressively in either direction. Short interest runs at around 4.8% of the free float — meaningful enough to track, but far from extreme. It edged up roughly 4.5% on the week to about 16.9 million shares, unwinding part of a sharper decline seen through May when shorts fell from nearly 20 million shares after the Q1 print. Borrowing is inexpensive at just 0.54%, and availability is deeply loose at 609% — nearly six shares available for every one already borrowed. That level of borrow supply, well above even the 52-week minimum of 340%, makes a squeeze dynamic implausible at this positioning. Short sellers face no structural pressure from the lending market.
The options market flashed a notable spike. The put/call ratio jumped to 0.19 on June 16 — over three standard deviations above its 20-day average of 0.03. For a REIT with options activity as thin as HR's, the absolute ratio is less telling than the relative jump; the 20-day baseline has been almost entirely call-dominated, so any meaningful put activity registers as an extreme. The spike likely reflects some single-session hedging activity rather than a wholesale shift in directional positioning. The broader picture from factor scores reinforces a neutral read: the short score of 45 is middling, the days-to-cover rank sits in the 18th percentile, and EPS momentum over 30 days is in the bottom few percentile ranks. Cheap on price-to-book at 1.77x, but EV/EBITDA of 16.4x leaves little room for error on earnings.
The bull and bear cases are genuinely in tension. On the positive side, Medical Office Buildings remain a defensive pocket within real estate — lower volatility, long lease structures, and proximity to hospital systems that are rationalising outpatient delivery. Q1 results came in well enough to prompt broad target increases, and the next earnings date is July 30, leaving a six-week window. The bear case centres on leverage, a dividend that was cut and has not been reinstated at prior levels based on available data, and competition from higher-growth REIT sectors for investor capital in a higher-rate-for-longer environment. Cantor Fitzgerald maintains Overweight with a $22 target; UBS, Citigroup, and Wells Fargo cluster around Neutral with targets near $20-21. The split between the more constructive names and the cautious majority is the clearest expression of the bull-bear divide.
Peer performance adds context to HR's relative resilience. Closest peer DOC fell 2.0% on the week while WELL gained 3.3% and VTR added 1.7%. HR's own 0.59% weekly gain puts it roughly in the middle of the healthcare REIT pack — neither a standout winner nor a laggard. SBRA and XRN both declined roughly 2-3%, suggesting the sector is splitting between the larger diversified names holding up and the smaller or more leveraged ones drifting lower.
The July 30 earnings report is the next hard data point — watch whether same-store NOI growth trends confirm or undercut the constructive tone from the Raymond James reinstatement, and whether the spread between Outperform-rated targets and the Neutral cluster narrows or widens as that date approaches.
See the live data behind this article on ORTEX.
Open HR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
